ACXP Quote, Financials, Valuation and Earnings

Modular Medical has a net margin of -- compared to Acurx Pharmaceuticals's net margin of --. Acurx Pharmaceuticals's return on equity of -- beat Modular Medical's return on equity of --.

Acurx Pharmaceuticals has a consensus price target of $6.70, signalling upside risk potential of 1593.85%. On the other hand Modular Medical has an analysts' consensus of $8.00 which suggests that it could grow by 684.31%. Given that Acurx Pharmaceuticals has higher upside potential than Modular Medical, analysts believe Acurx Pharmaceuticals is more attractive than Modular Medical.

Acurx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Modular Medical has a beta of -4.845, suggesting its less volatile than the S&P 500 by 584.542%.

Acurx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Modular Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals pays -- of its earnings as a dividend. Modular Medical pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals quarterly revenues are --, which are smaller than Modular Medical quarterly revenues of --. Acurx Pharmaceuticals's net income of -$2.8M is higher than Modular Medical's net income of -$4.8M. Notably, Acurx Pharmaceuticals's price-to-earnings ratio is -- while Modular Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals is -- versus -- for Modular Medical. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Acurx Pharmaceuticals's net margin of -49.65%. Acurx Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Acurx Pharmaceuticals has a consensus price target of $6.70, signalling upside risk potential of 1593.85%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 54.52%. Given that Acurx Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Acurx Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Acurx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Acurx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Acurx Pharmaceuticals's net income of -$2.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Acurx Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Acurx Pharmaceuticals's net margin of --. Acurx Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.

Acurx Pharmaceuticals has a consensus price target of $6.70, signalling upside risk potential of 1593.85%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 455.56%. Given that Acurx Pharmaceuticals has higher upside potential than Oragenics, analysts believe Acurx Pharmaceuticals is more attractive than Oragenics.

Acurx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Acurx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Acurx Pharmaceuticals's net income of -$2.8M is higher than Oragenics's net income of -$3.3M. Notably, Acurx Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals is -- versus 1.21x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Acurx Pharmaceuticals's net margin of --. Acurx Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Acurx Pharmaceuticals has a consensus price target of $6.70, signalling upside risk potential of 1593.85%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1252.66%. Given that Acurx Pharmaceuticals has higher upside potential than Theriva Biologics, analysts believe Acurx Pharmaceuticals is more attractive than Theriva Biologics.

Acurx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Acurx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Acurx Pharmaceuticals's net income of -$2.8M is higher than Theriva Biologics's net income of -$4.4M. Notably, Acurx Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.